A groundbreaking blood test in development by University of Cambridge researchers aims to provide accurate detection of prostate cancer, its aggressiveness, and the necessity for treatment. This test utilizes DNA methylation markers released by tumors, enabling the identification of cancer presence and severity levels through multiple signals simultaneously.
Unlike the current PSA test, which can yield false positives and miss aggressive cancers, this new blood test shows promise in addressing these limitations. Men who have undergone PSA testing may benefit from this new method without the need for invasive biopsies.
The research team at Cambridge is currently evaluating the precision of the blood test by analyzing samples from over 1,000 men across Europe and Africa. These samples, collected up to thirty years ago, are being studied to determine cancer development outcomes.
Clinical trials for the blood test are expected to commence within the next two years, focusing on its optimal placement in the screening process. Dr. Harveer Dev, leading the research at the Early Cancer Institute, highlighted the promising results of the ongoing development phase.
Dr. Naomi Elster, research director at Prostate Cancer Research, emphasized the need for more accurate diagnostic tools, praising the potential of the new blood test to provide critical information on cancer presence and severity for tailored treatment approaches.
Men showing symptoms of prostate cancer, such as urinary changes or blood in urine, are advised to consult their GP for PSA testing. The introduction of this innovative blood test could revolutionize prostate cancer screening and treatment strategies, offering new hope for improved accuracy and patient care.